Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, 428 Church St, Ann Arbor, Michigan 48109, United States.
Departments of Biological Sciences and of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 915 W State St, West Lafayette, Indiana 47907, United States.
J Med Chem. 2021 Jan 14;64(1):566-585. doi: 10.1021/acs.jmedchem.0c01522. Epub 2021 Jan 4.
The ability of G protein-coupled receptor (GPCR) kinases (GRKs) to regulate the desensitization of GPCRs has made GRK2 and GRK5 attractive targets for treating diseases such as heart failure and cancer. Previously, our work showed that Cys474, a GRK5 subfamily-specific residue located on a flexible loop adjacent to the active site, can be used as a covalent handle to achieve selective inhibition of GRK5 over GRK2 subfamily members. However, the potency of the most selective inhibitors remained modest. Herein, we describe a successful campaign to adapt an indolinone scaffold with covalent warheads, resulting in a series of 2-haloacetyl-containing compounds that react quickly and exhibit three orders of magnitude selectivity for GRK5 over GRK2 and low nanomolar potency. They however retain a similar selectivity profile across the kinome as the core scaffold, which was based on Sunitinib.
G 蛋白偶联受体激酶(GRK)能够调节 G 蛋白偶联受体的脱敏作用,这使得 GRK2 和 GRK5 成为治疗心力衰竭和癌症等疾病的有吸引力的靶点。此前,我们的工作表明,位于活性位点附近的柔性环上的 GRK5 亚家族特异性残基 Cys474 可用作共价接头,以实现对 GRK5 相对于 GRK2 亚家族成员的选择性抑制。然而,最具选择性的抑制剂的效力仍然不大。本文描述了一项成功的计划,即将含共价弹头的吲哚啉酮支架进行适应性改造,得到了一系列含 2-卤乙酰基的化合物,它们反应迅速,对 GRK5 的选择性是 GRK2 的三个数量级,对 GRK5 的效力低至纳摩尔级。然而,它们在激酶组中的选择性与基于舒尼替尼的核心支架相似。